273 results about "Mycobacterium Infections" patented technology

Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.

Calanolides and analogues thereof that demonstrate potent mycobacterium activity are provided. Also provided is a method of using calanolides and analogues thereof for treating or preventing mycobacterium infections. The calanolides and analogues thereof provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.

The invention relates to a method adopting double-label probe detection and melting curve analysis for diagnosing the infection of multi-drug resistant mycobacterium tuberculosis and a kit which utilizes the method to detect multiple gene mutations related to drug resistant tuberculosis at the same time, and the invention belongs to the life science and biological technical field. The kit of the invention contains a primer designed for multiple gene mutations related to drug resistant, a double-label oligonucleotide probe capable of detecting multiple common gene mutation sites related to drug resistant tuberculosis and a DNA polymerases with heat stability and without 5' nuclease activity, and the kit can be used to detect at least 16 common gene mutation sites related to drug resistant tuberculosis under proper PCR reaction conditions. The detection method and kit of the invention can be used in the early diagnosis of multi-drug resistant tuberculosis and overcome the problems of the existing technology that the detection time is long, a great deal of manpower and large material resources are needed, the detection cost is high, etc.

Mycobacterial proteins from culture filtrate or cytosol are disclosed as being useful B cell antigens for early diagnosis of mycobacterial disease, particularly in humans. These proteins include four that had not previously been recognized as B cell antigens (LppZ protein encoded by Mtb gene Rv3006; SodC protein encoded by Mtb gene Rv0432; BfrB protein encoded by Mtb gene Rv3841 and TrxC protein encoded byMtb gene Rv3914). Antigenic compositions include these proteins and / or peptide fragments thereof, in various combinations with each other or with one or more of a set of 10 additional Mtb proteins known to be antigens (in paricular early antigens. Methods and kits for using these antigenic composition for early diagnosis of mycobacterial infection and disease are also disclosed.

The present invention includes methods, systems and kits for distinguishing between active and latent mycobacterium tuberculosis infection in a patient suspected of being infected with mycobacterium tuberculosis, and distinguishing such patients from uninfected individuals, the method including the steps of obtaining a gene expression dataset from a whole blood obtained sample from the patient and determining the differential expression of one or more transcriptional gene expression modules that distinguish between infected and non-infected patients, wherein the dataset demonstrates an aggregate change in the levels of polynucleotides in the one or more transcriptional gene expression modules as compared to matched non- infected patients, thereby distinguishing between active and latent mycobacterium tuberculosis infection.

Compositions and methods for enhancing the immunity of a subject or vaccinating a subject against mycobacterial infections are disclosed. The invention provides compositions comprising formalin inactivated cultures of a mycobacterium, such as M. bovis, and a Novasome® adjuvant, as well as methods for using such compositions.

The invention belongs to the field of biomedicine examination, and particularly relates to a kit and a method for detecting mycobacterium tuberculosis infection and application. The invention discloses a novel mycobacterium tuberculosis detection reagent by screening specific T cell epitope of mycobacterium tuberculosis, wherein the reagent contains polypeptide or analog thereof represented by SEQ ID No.1-10. The method detects cell factors released from T cells by using single or more SEQ ID No.1-10 polypeptides to contact the T cells of mycobacterium tuberculosis infected individuals. The method can effectively detect active tuberculosis or latent tuberculosis infection, and is free from disturbance of Bacilli Calmette Guerin (BCG) inoculation vaccines. The invention also discloses a diagnostic kit and other application based on the polypeptide and the method. Compared with the gamma interferon release experiments in the prior art, the method can obviously improve the detection rate without reducing the specificity and has high clinical application value.

The present invention includes methods, systems and kits for distinguishing between active and latent mycobacterium tuberculosis infection in a patient suspected of being infected with mycobacterium tuberculosis, and distinguishing such patients from uninfected individuals, the method including the steps of obtaining a gene expression dataset from a whole blood obtained sample from the patient and determining the differential expression of one or more transcriptional gene expression modules that distinguish between infected and non-infected patients, wherein the dataset demonstrates an aggregate change in the levels of polynucleotides in the one or more transcriptional gene expression modules as compared to matched non-infected patients, thereby distinguishing between active and latent mycobacterium tuberculosis infection.

A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram poitive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.

Antibacterial antisense compounds and methods of their use in treating a Mycobacterium tuberculosis infection in a mammalian host are disclosed. The compounds include an antisense oligonucleotide conjugated to a carrier peptide that significantly enhances the antibacterial activity of the oligonucleotide. The antisense oligonucleotides contain 10-20 nucleotide bases and have a targeting nucleic acid sequence complementary to a target sequence containing or within 20 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication, where the compound binds to a target mRNA with a Tm of between 45° to 60° C. The carrier peptide is an arginine-rich peptide containing between 6 and 14 amino acids. Antisense compounds that target host factor genes that facilitate Mycobacterium tuberculosis infection are also provided, as are methods of using these compounds to treat Mycobacterium tuberculosis infections, alone or in combination with other therapies.

The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.

The invention identifies a narrow subset of Mycobacterium latency associated antigens and or epitopes that are capable of eliciting an immune response in vivo and in vitro in a mammal. The invention provides methods and compositions for detection and immunization against latent Mycobacterium infections. These compositions comprise those Mycobacterial latency antigens that are actually capable of eliciting an immune response in vivo, in mammals experiencing a latent Mycobacterium infection. More preferably the compositions comprise those antigens that are preferentially recognized by latently infected individuals and which antigens are not, or to a much lesser extent, recognized in individuals having an active Mycobacterium infection or in individuals having Mycobacterium induced symptoms or diseases, such as in patients infected with M. tuberculosis suffering from tuberculosis disease (TB).

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin / low molecular weight heparin derivative.

Methods and compositions for the detection of disease caused by infectious agents and microbes are provided. In particular, methods and compositions comprising novel combinations of nucleic acid amplification and drug susceptibility technologies are provided. In certain embodiments, the present invention enables the detection of infectious agents and microbes as well as providing information concerning the viability status of the agent or microbe. In one embodiment, the present invention is used for the detection of mycobacterial infections, including, but not limited to, tuberculosis.

The methods of the invention can be used to treat mycobacterial infections, or any disease or disorder that is caused by (or aggravated by) an intracellular pathogen. Accordingly, the invention features methods for treating a subject who has a disorder that is associated with an intracellular pathogen by administering, to a subject, a molecular conjugate that includes a photosensitizer (a term used herein to refer to a light activatable compound) and a targeting moiety, the targeting moiety being capable of targeting the conjugate to the intracellular pathogen.

The invention discloses certain mycobacterium tuberculosis specific antigen epitope polypeptides, and particularly discloses an antigen Pv3615c antigen epitope polypeptide consisting of 8-11 continuous polypeptide fragments. The clinical detection practicability of the antigen polypeptide is evaluated according to the reaction sensitivity and specificity of the antigen polypeptide in a tuberculosis case. As proved by a result, an antigen polypeptide has high T cell reactivity in a tuberculosis patient, and the positive rate is up to 64 percent (9 / 14). Compared with the result of a healthy volunteer, the antigen epitope polypeptide has the specificity of up to 100 percent (6 / 6). Mycobacterium tuberculosis infection can be diagnosed effectively by applying an antigen peptide library specific T cell gamma interferon.

Compounds and methods for diagnosing tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of one or more M. tuberculosis proteins, and DNA sequences encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of M. tuberculosis infection in patients and biological samples. Antibodies directed against such polypeptides are also provided.

Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.

The invention identifies a narrow subset of Mycobacterium latency associated antigens and or epitopes that are capable of eliciting an immune response in vivo and in vitro in a mammal. The invention provides methods and compositions for detection and immunization against latent Mycobacterium infections. These compositions comprise those Mycobacterial latency antigens that are actually capable of eliciting an immune response in vivo, in mammals experiencing a latent Mycobacterium infection. More preferably the compositions comprise those antigens that are preferentially recognized by latently infected individuals and which antigens are not, or to a much lesser extent, recognized in individuals having an active Mycobacterium infection or in individuals having Mycobacterium induced symptoms or diseases, such as in patients infected with M. tuberculosis suffering from tuberculosis disease (TB).

The present invention relates to new attenuated M. bovis bacteria strains passaged at least 110 times. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of any of those attenuated M. bovis bacteria strain, their manufacture and use for the treatment and prophylaxis of M. bovis infections and combinations with other veterinary vaccines or medicaments.

Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of Formula (Ia) or (Ib)a pharmaceutically acceptable acid or base addition salt thereof, a quaternary amine thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N-oxide form thereof, wherein R1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2 or 3; R2 is hydrogen; alkyl; hydroxy; mercapto; optionally substituted alkyloxy; alkyloxyalkyloxy; alkylthio; mono or di(alkyl)amino wherein alkyl may optionally be substituted; Ar; Het or a radical of formulaR3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; q is zero, 1, 2, 3 or 4; X is a direct bond or CH2; R4 and R5 each independently are hydrogen, alkyl or benzyl; or R4 and R5 may be taken together including the N to which they are attached; R6 is hydrogen or a radical of formulaR7 is hydrogen, alkyl, Ar or Het; R8 is hydrogen or alkyl; R9 is oxo; or R8 and R9 together form the radical —CH═CH—N═; and R11 is as defined in the claims.

Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising novel diamine compositions for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin / low molecular weight heparin derivative.

The present invention provides isolated M. tuberculosis protein that is a putative Ketol-acid reductoisomerase (KARI; SEQ ID NO: 1) and immunogenic peptide fragments thereof, and antibodies produced against the full-length protein and immunogenic peptide fragments for the diagnosis of tuberculosis and / or infection by one or more mycobacteria of the M. tuberculosis complex in humans, for example using an antigen-based sandwich ELISA format. The present invention also provides multianalyte assays in which the KARI-based diagnostic assays of the present invention are multiplexed with the detection of one or more immunogenic epitopes from one or more other proteins of said mycobacteria e.g., anyone of SEQ IDS NOs: 2, 14, 21, 28-29, 36, or 44, including any combinations thereof.

The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a method of identifying an active M. tuberculosis infection. In another embodiment, the present invention contemplates a method of monitoring a M. tuberculosis infection. In yet another embodiment, the present invention contemplates a method of monitoring a patient's response to treatment for an active M. tuberculosis infection. In a further embodiment, the present invention contemplates a method of monitoring a patient's response to treatment for an active M. tuberculosis infection.

Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibiting M. tuberculosis-infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or a M. tuberculosis-infected cell, wherein a T cell is contacted with an APC that is modified to present an hsp110 or grp170 polypeptide and an immunogenic polypeptide associated with a tumor or with the M. tuberculosis-infected cell. Included in the invention are T cells produced by this method and a pharmaceutical composition comprising such T cells. The T cells can be contacted with a M. tuberculosis-infected cell in a method for killing a M. tuberculosis-infected cell, or with a tumor cell in a method for killing a tumor cell.

The present invention provides a method of specifically detecting the presence of one or more Mycobacteria of the M. tuberculosis complex, said method comprising detecting ilvC nucleic acid of one or more Mycobacteria of the M. tuberculosis complex in a sample under conditions that do not detect ilvC nucleic acid of the M. avium complex. The invention also provides methods of diagnosis and treatment of tuberculosis in a subject employing the specific detection ilvC nucleic acid of one or more Mycobacteria of the M. tuberculosis complex.

Compositions and methods for enhancing the immunity of a subject or vaccinating a subject against mycobacterial infections are disclosed. The invention provides compositions comprising formalin inactivated cultures of a mycobacterium, such as M. bovis, and a Novasome® adjuvant, as well as methods for using such compositions.

The invention provides novel Class I HLA-A2 and Class II HLA-DR4-restricted epitopes and methods for their use in detecting T-cells in peripheral blood specific for infection or latency of mycobacterial infection, including M. tuberculosis and M. leprae as others. For example, methods for diagnosing the presence of infection or exposure by M. tuberculosis utilize multimers of HLA monomers or modified monomers having a bound HLA-binding peptide to perform high throughput screening of patient PBLs. The methods can be used for monitoring the success of anti mycobacterial treatment in patients and to screen vaccines and drugs for effectiveness in treating or preventing exposure, infection and latency of mycobacteria in humans.

A method of diagnosing Mycobacterium tuberculosis infection in a human, or of determining whether a human has been exposed to Mycobacterium tuberculosis, comprising (i) contacting T-cells from said human with one or more of (a) a peptide having the sequence shown in SEQ ID NO 20, (b) a peptide having or comprising the sequence of at least 8 consecutive amino acids of the sequence shown in SEQ. ID NO 20; or (c) a peptide having or comprising a sequence which is capable of binding to a T-cell receptor which recognises a peptide as defined in (a) or (b); and (ii) determining whether any of the said T-cells recognise said peptide, wherein steps (i) and (ii) are optionally carried out in vitro. The peptide is the product of the RV3615c gene.